» Articles » PMID: 22043900

Interleukin-32 Enhances Cytotoxic Effect of Natural Killer Cells to Cancer Cells Via Activation of Death Receptor 3

Overview
Journal Immunology
Date 2011 Nov 3
PMID 22043900
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Studies have demonstrated that the anti-tumour effect of natural killer (NK) cells is successful for patients with several cancers. Although interleukin-32 (IL-32) is endogenously expressed in NK cells, cytolytic function of NK cells against cancer cells has not been fully demonstrated. In the present study, we found that the growth of cancer cells was suppressed when colon cancer cells or prostate cancer cells were co-cultured with NK-92 cells, an NK cell line. We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in PC3 cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells. However, cancer cell growth inhibition and IL-32 expression were abolished when cancer cells were co-cultured with NK cells transfected with small interfering (si) RNA of IL-32. DR3 expression was also diminished by co-culture with IL-32-specific siRNA-transfected NK-92 cells. Expression of APO3L, a ligand of DR3, was elevated in NK cells that were co-cultured with cancer cells. It was also found that expression of apoptosis-related proteins such as cleaved caspase-3 and bax was increased in cancer cells co-cultured with NK-92 cells, but their expression was abolished by co-culture with IL-32 siRNA-transfected NK-92 cells. Moreover, knockdown of DR3 in co-culture of NK-92 cells with cancer cells by siRNA or antibodies of DR3 and APO3L reversed the growth inhibitory effect of NK-92 cells. In conclusion, our study showed that IL-32 enhanced the cytotoxic effect of NK-92 cells on the cancer cells through activation of DR3 and caspase-3.

Citing Articles

Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.

Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.

PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.


Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment.

Tran M, Youssef D, Shroff S, Chowhan D, Beaumont K, Sebra R J Exp Med. 2024; 221(8).

PMID: 38847806 PMC: 11157455. DOI: 10.1084/jem.20240045.


Role of interleukin‑32 in cancer progression (Review).

Meng D, Dong H, Wang C, Zang R, Wang J Oncol Lett. 2024; 27(2):54.

PMID: 38192653 PMC: 10773214. DOI: 10.3892/ol.2023.14187.


Cell Type Catalog of Middle Turbinate Epithelium ().

Mathews F, Tung V, Foronjy R, Boruk M, Knowles J, Evgrafov O OTO Open. 2023; 7(4):e91.

PMID: 38093720 PMC: 10718469. DOI: 10.1002/oto2.91.


Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity.

Dos Reis F, Jeronimo C, Correia M Front Immunol. 2023; 14:1152572.

PMID: 37090711 PMC: 10113550. DOI: 10.3389/fimmu.2023.1152572.


References
1.
Ferlazzo G, Pack M, Thomas D, Paludan C, Schmid D, Strowig T . Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A. 2004; 101(47):16606-11. PMC: 534504. DOI: 10.1073/pnas.0407522101. View

2.
Hyodo Y, Matsui K, Hayashi N, Tsutsui H, Kashiwamura S, Yamauchi H . IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol. 1999; 162(3):1662-8. View

3.
Carson W, Parihar R, Lindemann M, Personeni N, Dierksheide J, Meropol N . Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol. 2001; 31(10):3016-25. DOI: 10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j. View

4.
Margolin K . Interleukin-2 in the treatment of renal cancer. Semin Oncol. 2000; 27(2):194-203. View

5.
Berg M, Lundqvist A, McCoy Jr P, Samsel L, Fan Y, Tawab A . Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009; 11(3):341-55. PMC: 2736058. DOI: 10.1080/14653240902807034. View